YourVoice.Now Summary
Your MoneyCorporate BenefitsTransparency & AccountabilityThe program that finds marrow and cord blood donors would run through 2031 — with new rules on which donations get kept.
Your Money
This is the federal program that matches patients with unrelated bone marrow and cord blood donors. Funding would go from about $31 million a year to about $33 million for 2027 through 2031.
The bill would spell out what counts as a high-quality cord blood unit. It must meet current industry standards and FDA rules.
Health officials would have to keep the stored units varied by genetic type. A match depends on tissue types you are born with. A wider mix fits more patients.
If a bank shuts down or fails quality rules, it may no longer hand out its units. Health officials could then move those units to another approved bank so patients can still use them.
Today banks agree to store donated units forever. That promise would come out of the law, and officials could decide which units to keep or discard.
Corporate Benefits
To take part, a bank would have to agree that the government may move its units elsewhere. That call would sit with health officials, not the bank.
Transparency & Accountability
A standing review of stem cell science would grow to cover high-quality cord blood units and other new tools. It would restart a year after the bill became law. A report would be due three years after that.
Current law names a target of at least 150,000 new units. The bill would swap that number for a sufficient supply, as the Secretary of Health and Human Services decides.
The current funding approval runs out in 2026. Extending it to 2031 means the next required look by Congress comes five years later.
More about this bill
Patients who need a bone marrow or cord blood transplant use a national program to find a matching donor. That program would keep running for five more years, through 2031. Its yearly funding would rise to about $33 million, up from about $31 million. Most people would see no change in daily life. Rules for the national cord blood supply would change more. Today the law sets a goal of at least 150,000 new units. That fixed number would go away. Health officials would instead decide how large the supply should be. They would manage it for quality, genetic variety, and cost. Banks would no longer promise to keep donated units forever. Officials could move units out of a bank that closes or fails quality standards. They could also decide which units to keep or discard.
Congressional Summary
Stem Cell Therapeutic and Research Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Legislative Subjects
Details
- Congress
- 119th
- Chamber
- Senate
- Status
- summarized
- Action
- Reported to Senate
- Action Date
- 2026-06-22
- Date Added
- 2026-07-23
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.